Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Need for innovative treatments for HL: Creating a benchmark

Paul Jan Bröckelmann • 15 Jun 2019
EHA 2019
Hodgkin Lymphoma Lymphoma

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses a recent publication on the outcomes of patients with third or higher relapsed classical Hodgkin lymphoma from the German Hodgkin Study Group at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. The study Dr Bröckelmann mentions has allowed for the development of a benchmark for Hodgkin lymphoma and will help a patient group in need of innovative agents.

More from Paul Jan Bröckelmann

The growing role of anti-PD1 inhibitors in the frontline treatment of HL
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
The importance of individualizing treatment approaches in HL to improve patient outcomes
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
Recent clinical developments in the treatment landscape for older patients with HL
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals